Pifithrin-μ in conjunction with sorafenib exerts the therapeutic potential in the treatment of TSC2-deficient human liver cancer cell-derived xenograft tumors and spontaneous mouse liver cancer. This evidence concerns the gene TSC2 and liver cancer.